Multimedia Available: FDA Approves Amgen's Neulasta for Serious & Frequent Chemotherapy Side Effect| Amgen

Multimedia Available: FDA Approves Amgen's Neulasta for Serious & Frequent Chemotherapy Side Effect

Amgen (Nasdaq:AMGN) announced that the U.S. Food and Drug Administration has approved Neulasta(TM) (pegfilgrastim). Neulasta, administered as a single fixed dose per chemotherapy cycle, for decreasing the incidence of infection, as manifested by febrile neutropenia (fever associated with a severe drop in infection-fighting white blood cells) in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?4945

This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics, and photos.

If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.

--30--LS/na*

CONTACT: Newstream
info@newstream.com